Drugs / ART5803
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06753955 | Feb → Jul 2025 | anti-NMDA receptor encephalitis, autoimmune encephalitis | Arialys Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT06575153 | Sep 2024 → Sep 2025 | autoimmune encephalitis | Arialys Therapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07093333 | May 2026 → Nov 2027 expected | anti-NMDA receptor encephalitis, autoimmune encephalitis | Arialys Australia Pty Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ART5803 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07093333 ↗ |
| Modality | Protein / enzyme biologic | “a monovalent (one-armed) antibody” NCT07093333 ↗ |
| Route | Intravenous | “IV infusion” NCT06575153 ↗ |